CN105745204A - 用于治疗肾脏疾病的阿曲生坦扁桃酸盐 - Google Patents

用于治疗肾脏疾病的阿曲生坦扁桃酸盐 Download PDF

Info

Publication number
CN105745204A
CN105745204A CN201480061886.9A CN201480061886A CN105745204A CN 105745204 A CN105745204 A CN 105745204A CN 201480061886 A CN201480061886 A CN 201480061886A CN 105745204 A CN105745204 A CN 105745204A
Authority
CN
China
Prior art keywords
salt
atrasentan
mandelate
mandelic acid
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480061886.9A
Other languages
English (en)
Chinese (zh)
Inventor
龚豫川
G.G.张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52472936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105745204(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CN105745204A publication Critical patent/CN105745204A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50—Mandelic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN201480061886.9A 2013-09-12 2014-09-10 用于治疗肾脏疾病的阿曲生坦扁桃酸盐 Pending CN105745204A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361877101P 2013-09-12 2013-09-12
US61/877101 2013-09-12
US14/133,297 US8962675B1 (en) 2013-09-12 2013-12-18 Atrasentan mandelate salts
US14/133297 2013-12-18
PCT/US2014/054888 WO2015038571A1 (en) 2013-09-12 2014-09-10 Atrasentan mandelate salts for the treatement of kidney diseases

Publications (1)

Publication Number Publication Date
CN105745204A true CN105745204A (zh) 2016-07-06

Family

ID=52472936

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480061886.9A Pending CN105745204A (zh) 2013-09-12 2014-09-10 用于治疗肾脏疾病的阿曲生坦扁桃酸盐

Country Status (9)

Country Link
US (3) US8962675B1 (enExample)
EP (2) EP3044222B1 (enExample)
JP (1) JP2016530311A (enExample)
CN (1) CN105745204A (enExample)
AU (1) AU2014318924A1 (enExample)
CA (1) CA2923627C (enExample)
CL (1) CL2016000583A1 (enExample)
MX (1) MX2016003065A (enExample)
WO (1) WO2015038571A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016103764A (ru) * 2013-07-08 2017-08-11 Эббви Инк. Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан
CN105905245B (zh) * 2016-06-03 2018-12-25 青岛北海船舶重工有限责任公司 用于水面无人艇布放回收的吊笼
CN116173014A (zh) 2019-12-17 2023-05-30 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
CR20230083A (es) 2020-07-10 2023-05-16 Astrazeneca Ab Combinación de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal crónica
CN120302971A (zh) 2022-10-28 2025-07-11 奇努克治疗公司 使用内皮素受体拮抗剂和april结合抗体治疗iga肾病

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
WO2002017912A1 (en) * 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
WO2006034094A1 (en) * 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US7208517B1 (en) * 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
DE69527072T2 (de) * 1994-08-19 2003-02-13 Abbott Laboratories, Abbott Park Endothelin antagoniste
US6124341A (en) 1996-02-13 2000-09-26 Abbott Laboratories Endothelin antagonists
US5801250A (en) 1996-12-13 1998-09-01 Abbott Laboratories Process for the stereoselective production of nitro-enamine compounds
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2002524546A (ja) 1998-09-14 2002-08-06 アボット・ラボラトリーズ 立体選択性ニトロ化合物の製造方法
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030022811A1 (en) 2001-04-11 2003-01-30 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
UA79248C2 (en) * 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
US20060135596A1 (en) * 2004-09-17 2006-06-22 Zhang Geoff G Amorphous form of a drug
US20060063825A1 (en) * 2004-09-17 2006-03-23 Walter Dziki Crystalline form of a drug
US20080132710A1 (en) 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
EP2294047A2 (en) * 2008-04-04 2011-03-16 Actavis Group PTC EHF Novel mandelate salt of fesoterodine
US20100184026A1 (en) 2009-01-22 2010-07-22 Abbott Laboratories Companion Diagnostic Assays For Endothelin Receptor Antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
WO2002017912A1 (en) * 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
WO2006034094A1 (en) * 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride

Also Published As

Publication number Publication date
US20150073031A1 (en) 2015-03-12
US9637476B2 (en) 2017-05-02
CA2923627A1 (en) 2015-03-19
EP3044222A1 (en) 2016-07-20
AU2014318924A1 (en) 2016-03-17
JP2016530311A (ja) 2016-09-29
US20170190692A1 (en) 2017-07-06
US20150126574A1 (en) 2015-05-07
CA2923627C (en) 2022-06-21
MX2016003065A (es) 2016-05-26
EP3044222B1 (en) 2017-07-05
WO2015038571A1 (en) 2015-03-19
US8962675B1 (en) 2015-02-24
EP3239148A1 (en) 2017-11-01
CL2016000583A1 (es) 2016-11-11

Similar Documents

Publication Publication Date Title
CN110922366B (zh) 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
US20170190692A1 (en) Atrasentan mandelate salts
JP6328737B2 (ja) Ｌ−オルニチンフェニルアセテートおよびその製造方法
KR101791724B1 (ko) 결정질 날록솔-ｐｅｇ 접합체
AU2017202081B2 (en) L-ornithine phenyl acetate and methods of making thereof
CN106414416A (zh) 结晶型ARB‑NEPi复合物及其制备方法和应用
ES2966219T3 (es) Fosfato de tapentadol amorfo
WO2016051393A2 (en) Crystalline form iv of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
KR20220062510A (ko) (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의 고체 상태 형태 및 이의 용도
TW201722950A (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
HK1226402A1 (en) Atrasentan mandelate salts for the treatement of kidney diseases
HK1226402B (en) Atrasentan mandelate salts for the treatement of kidney diseases
JP2024542115A (ja) リナプラザングルレートのメシラート塩の多形体
WO2020151672A1 (zh) 一种达格列净晶型及其制备方法和用途
HK40033714A (en) L-ornithine phenyl acetate and methods of making thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160706